Results 31 to 40 of about 2,385 (197)

Safety of Intravenous Cangrelor Versus Dual Oral Antiplatelet Loading Therapy in Endovascular Treatment of Tandem Lesions: An Observational Cohort Study

Stroke: Vascular and Interventional Neurology, 2023
Background Procedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. We aimed to compare the safety profile of low‐dose intravenous cangrelor versus dual oral antiplatelet ...
Aaron Rodriguez‐Calienes, Marion Oliver, Ameer E. Hassan, Juan Vivanco‐Suarez, Afshin A. Divani, Marc Ribo, Nils Petersen, Michael Abraham, Johanna Fifi, Waldo R. Guerrero, Amer M. Malik, James E. Siegler, Thanh Nguyen, Sunil Sheth, Albert Yoo, Guillermo Linares, Nazli Janjua, Darko Quispe‐Orozco, Milagros Galecio‐Castillo, Hisham Alhajala, Marco Malaga, Mudassir Farooqui, Tudor Jovin, Mouhammad Jumaa, Santiago Ortega‐Gutierrez   +24 more
doaj   +1 more source

Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction [PDF]

, 2020
BACKGROUND Standard administration of newer oral P2Y$_{12}$ inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition of platelet aggregation (IPA) in patients with ST-segment-elevation myocardial infarction undergoing primary ...
Giovanni Esposito, Gianluca Campo, Gragnano, Felice, Marisa Avvedimento, Pietro Minuz, Negar Manavifar, Lukas Hunziker, Campo, Gianluca, Leonardi, Sergio, Giuseppe Gargiulo, Tebaldi, Matteo, Vranckx, Pascal, Marco Valgimigli, Manavifar, Negar, Michael Nagler, Plinio Cirillo, Avvedimento, Marisa, Sergio Leonardi, Heg, Dik, Matteo Tebaldi, Esposito, Giovanni, Windecker, Stephan, Pascal Vranckx, Gargiulo, Giuseppe, Piccolo, Raffaele, Cirillo, Plinio, Stephan Windecker, Dik Heg, Hunziker, Lukas, Nagler, Michael, Felice Gragnano, Raffaele Piccolo, Minuz, Pietro, Valgimigli, Marco   +33 more
core   +1 more source

Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program

American Heart Journal Plus, 2021
Background: Peripheral artery disease (PAD) is associated with an increased risk of ischemic events following percutaneous coronary intervention (PCI). More aggressive antiplatelet therapy may mitigate this risk.
J. Antonio Gutierrez, Robert A. Harrington, Gregg W. Stone, Ph. Gabriel Steg, C. Michael Gibson, Christian W. Hamm, Matthew J. Price, Renato D. Lopes, Sergio Leonardi, Jayne Prats, Efthymios N. Deliargyris, Kenneth W. Mahaffey, Harvey D. White, Deepak L. Bhatt   +13 more
doaj   +1 more source

Intravenous Platelet Blockade with Cangrelor during PCI [PDF]

, 2009
BACKGROUND: Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI).
Manukov, Ivan, McNulty, Stephen, Jafar, M. Zubair, Cura, Fernando, Gibson, C. Michael, Goodman, Shaun G, Lincoff, A. Michael, Lincoff, A Michael, Arneja, Jaspal, Tousek, Frantisek, Pollack, Charles V, Skerjanec, Simona, Harrington, Robert A, Goodman, Shaun G., Gibson, C Michael, Chew, Derek Peng, Montalescot, Gilles, Bhatt, Deepak L., Bhatt, Deepak L, White, Harvey D, Kleiman, Neal S., White, Harvey D., McNulty, Steven, Manoukian, Steven V, Mahaffey, Kenneth W, Kleiman, Neal S, Stone, Gregg W., Widimsky, Petr, Stone, Gregg W, Manoukian, Steven V., Chew, Derek P., Harrington, Robert A., Mahaffey, Kenneth W., Pollack, Charles V., Jafar, M Zubair   +34 more
core   +1 more source

Ruptured blister-type cerebral aneurysm pathogenesis and treatment with flow diversion using a novel antiplatelet agent cangrelor

Interdisciplinary Neurosurgery, 2021
Ruptured blister type aneurysms are challenging to treat, and the ideal treatment remains debated. Recently, endovascular procedures, particularly flow diversion, gained popularity in treating blister aneurysms; however, the need for dual antiplatelet ...
Taylor Anne Wilson, Dinesh Ramanathan, Justin Dye   +2 more
doaj   +1 more source

Cangrelor in STEMI as a bridge to CABG- a mini-case series

American Heart Journal Plus, 2022
Background: Patients with STEMI receive dual antiplatelet therapy as soon as possible with aspirin and a P2Y12 receptor antagonist prior to PCI. A fraction of these patients may have multi-vessel disease needing emergent CABG surgery.
Bishesh Shrestha, Daniel Katz, John Kelley, Dhananjai Menzies, Mun K. Hong   +4 more
doaj   +1 more source

Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry [PDF]

, 2023
The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (ClincalTrials.gov: NCT04790032) is a prospective study conducted at Federico II University of ...
Paolillo, Roberta, Borgia, Francesco, Stabile, Eugenio, Esposito, Giovanni, Sperandeo, Luca, Marenna, Alessandra, Gargiulo, Giuseppe, Canonico, Mario Enrico, Diserafino, Luigi, Piccolo, Raffaele, Manzi, Lina, Cirillo, Plinio, Simonetti, Fiorenzo, Franzone, Anna, Spinelli, Alessandra, Avvedimento, Marisa, Valgimigli, Marco   +16 more
core   +1 more source

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience

TH Open, 2020
Objective The aim of the study is to describe the real-world use of the P2Y12 inhibitor cangrelor as a bridging strategy in patients at high thrombotic risk after percutaneous coronary intervention (PCI) and referred to surgery requiring perioperative ...
Roberta Rossini, Giulia Masiero, Claudia Fruttero, Enrico Passamonti, Elba Calvaruso, Moreno Cecconi, Cesare Carlucci, Marco Mojoli, Parodi Guido, Giuseppe Talanas, Simona Pierini, Paolo Canova, Nicoletta De Cesare, Stefania Luceri, Nicoletta Barzaghi, Giulio Melloni, Giorgio Baralis, Alessandro Locatelli, Giuseppe Musumeci, Dominick J. Angiolillo   +19 more
doaj   +1 more source

Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a Case Series

Cellular Physiology and Biochemistry, 2017
Background/Aims: Patients with acute coronary syndromes (ACS) presenting with cardiogenic shock (CS) are at particular risk for death and adverse cardiac events.
Michal Droppa, Oliver Borst, Dominik Rath, Karin Müller, Meinrad Gawaz, Deepak L. Bhatt, Tobia Geisler   +6 more
doaj   +1 more source

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention

Cardiology Journal, 2023
BACKGROUND: Myocardial reperfusion is the main target of treatment in patients with ST-segment elevation myocardial infarction (STEMI). The intracoronary administration of cangrelor bolus could favor a higher local drug concentration, favoring an earlier
Iacopo Muraca, Matteo Pennesi, Alessio Mattesini, Angela Migliorini, Nazario Carrabba, Giacomo Virgili, Filippo Bruscoli, Pierluigi Demola, Riccardo Colombi, Giulia Pontecorboli, Niccolò Marchionni, Carlo Di Mario, Renato Valenti   +12 more
doaj   +1 more source